The Europe plasmid DNA manufacturing market was valued at USD 740 million in 2025 and is projected to reach USD 4,214.07 million by 2035, growing at a CAGR of 19% due to rising demand for gene therapies , DNA vaccines , and advanced biologics manufacturing.

Europe Plasmid DNA Manufacturing Market Statical Scope

Europe plasmid DNA manufacturing market provides essential genetic material for the creation of gene therapies, mRNA vaccines, and the development of advanced biologics.

Over the past 3 to 5 years, the market has evolved from producing small research batches to manufacturing large-scale products that comply with Good Manufacturing Practice (GMP) standards. The development of cell and gene therapy pipelines has accelerated this industry's growth, facilitating this transition.

Europe Plasmid DNA Manufacturing Market Share, By Grade, 2025 (%)

• GMP grade- Plasmid DNA produced under Good Manufacturing Practices for clinical and therapeutic use. The GMP grade segment dominated with 60% share due to its important role in the production of therapeutics and vaccines.
• R&D grade- Plasmid DNA manufactured for research and development purposes. This segment held 40% share, driven by growing investments in biotech and increasing focus on personalized medicine.

Europe Plasmid DNA Manufacturing Market Share, By Development Phase, 2025 (%)

• Clinical therapeutics- Plasmid DNA used in clinical trials for therapeutic development. The clinical therapeutics segment dominated with 45% share due to growing involvement in clinical trials and ongoing drug development.
• Marketed therapeutics- Plasmid DNA used in the final stages of therapeutic applications for approved treatments. The marketed therapeutics segment held 30% share, driven primarily by the increase in approved gene therapies.

Europe Plasmid DNA Manufacturing Market Share, By Application, 2025 (%)

• Cell & gene therapy- Plasmid DNA used in the production of cell and gene-based therapies. Cell & gene therapy held 35% share, growing fastest due to rapid advancements and increasing adoption in therapeutic applications.
• DNA vaccines- Plasmid DNA used in the creation of DNA-based vaccines. The DNA vaccines segment held 40% share, due to growing demand for cell & gene therapies in advanced treatments.

Europe Plasmid DNA Manufacturing Market Share, By Disease, 2025 (%)

• Cancer- Plasmid DNA used in the development of cancer treatments and vaccines. The cancer segment dominated with 40% share due to the growing prevalence of cancer and significant therapeutic development in oncology.
• Infectious disease- Plasmid DNA used in the development of treatments for infectious diseases. The infectious disease held 30% share, driven by growing advancements in mRNA vaccine development.

Top Companies in the Europe Plasmid DNA Manufacturing Market

• Charles River Laboratories
• VGXI, Inc.
• Danaher (Aldevron)
• Kaneka Corp.
• Cell and Gene Therapy Catapult
• Eurofins Genomics
• Lonza
• Luminous BioSciences, LLC
• Akron Biotech
• Catalent, Inc.

Segments Covered in the Report

By Grade

• GMP grade
• R&D grade

By Development Phase

• Clinical therapeutics
• Marketed therapeutics
• Pre-Clinical Therapeutics

By Application

• Cell & gene therapy
• DNA vaccines
• Immunotherapy
• Others

By Disease

• Cancer
• Genetic disorder
• Infectious Disease
• Others